NO992296L - FremgangsmÕte for disubstituerte pyridiner - Google Patents

FremgangsmÕte for disubstituerte pyridiner

Info

Publication number
NO992296L
NO992296L NO992296A NO992296A NO992296L NO 992296 L NO992296 L NO 992296L NO 992296 A NO992296 A NO 992296A NO 992296 A NO992296 A NO 992296A NO 992296 L NO992296 L NO 992296L
Authority
NO
Norway
Prior art keywords
formula
amino
nitro
processes
preparation
Prior art date
Application number
NO992296A
Other languages
English (en)
Norwegian (no)
Other versions
NO992296D0 (no
Inventor
Keith Michael Devries
Robert Lee Dow
Stephen Wayne Wright
Original Assignee
Pfizer
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer filed Critical Pfizer
Publication of NO992296L publication Critical patent/NO992296L/no
Publication of NO992296D0 publication Critical patent/NO992296D0/no

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D213/00Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/72Nitrogen atoms
    • C07D213/73Unsubstituted amino or imino radicals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/06Antihyperlipidemics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/08Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D213/00Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/72Nitrogen atoms
    • C07D213/75Amino or imino radicals, acylated by carboxylic or carbonic acids, or by sulfur or nitrogen analogues thereof, e.g. carbamates
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02PCLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00Technologies relating to chemical industry
    • Y02P20/50Improvements relating to the production of bulk chemicals
    • Y02P20/55Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Diabetes (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Pyridine Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Plural Heterocyclic Compounds (AREA)
NO992296A 1996-11-14 1999-05-12 FremgangsmÕte for disubstituerte pyridiner NO992296D0 (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US3088096P 1996-11-14 1996-11-14
PCT/IB1997/001367 WO1998021184A1 (en) 1996-11-14 1997-11-03 Process for substituted pyridines

Publications (2)

Publication Number Publication Date
NO992296L true NO992296L (no) 1999-05-12
NO992296D0 NO992296D0 (no) 1999-05-12

Family

ID=21856496

Family Applications (1)

Application Number Title Priority Date Filing Date
NO992296A NO992296D0 (no) 1996-11-14 1999-05-12 FremgangsmÕte for disubstituerte pyridiner

Country Status (32)

Country Link
US (1) US6291489B1 (US06291489-20010918-C00020.png)
EP (1) EP0938476B1 (US06291489-20010918-C00020.png)
JP (1) JP3510635B2 (US06291489-20010918-C00020.png)
KR (1) KR20000053314A (US06291489-20010918-C00020.png)
CN (1) CN1237160A (US06291489-20010918-C00020.png)
AP (1) AP805A (US06291489-20010918-C00020.png)
AR (1) AR010584A1 (US06291489-20010918-C00020.png)
AT (1) ATE319687T1 (US06291489-20010918-C00020.png)
AU (1) AU4634697A (US06291489-20010918-C00020.png)
BG (1) BG103393A (US06291489-20010918-C00020.png)
BR (1) BR9712951A (US06291489-20010918-C00020.png)
CA (1) CA2270386C (US06291489-20010918-C00020.png)
CO (1) CO4930261A1 (US06291489-20010918-C00020.png)
DE (1) DE69735433D1 (US06291489-20010918-C00020.png)
EA (1) EA199900375A1 (US06291489-20010918-C00020.png)
GT (1) GT199700118A (US06291489-20010918-C00020.png)
HR (1) HRP970612A2 (US06291489-20010918-C00020.png)
ID (1) ID18898A (US06291489-20010918-C00020.png)
IL (1) IL129688A0 (US06291489-20010918-C00020.png)
IS (1) IS5029A (US06291489-20010918-C00020.png)
MA (1) MA24401A1 (US06291489-20010918-C00020.png)
MY (1) MY132507A (US06291489-20010918-C00020.png)
NO (1) NO992296D0 (US06291489-20010918-C00020.png)
OA (1) OA11044A (US06291489-20010918-C00020.png)
PA (1) PA8441401A1 (US06291489-20010918-C00020.png)
PE (1) PE10299A1 (US06291489-20010918-C00020.png)
TN (1) TNSN97172A1 (US06291489-20010918-C00020.png)
TR (1) TR199901063T2 (US06291489-20010918-C00020.png)
UY (1) UY24774A1 (US06291489-20010918-C00020.png)
WO (1) WO1998021184A1 (US06291489-20010918-C00020.png)
YU (1) YU22099A (US06291489-20010918-C00020.png)
ZA (1) ZA9710186B (US06291489-20010918-C00020.png)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1999052892A2 (en) * 1998-04-08 1999-10-21 Novartis Ag Novel herbicides
US6090942A (en) * 1998-10-15 2000-07-18 Pfizer Inc. Process and intermediates for a β3 -adrenergic receptor agonist
KR20010102198A (ko) * 1999-02-16 2001-11-15 후루타 타케시 치환 아세틸피리딘 유도체 및 그를 이용하는 광학활성 β3작용제 중간체의 제조 방법
US6455734B1 (en) 2000-08-09 2002-09-24 Magnesium Diagnostics, Inc. Antagonists of the magnesium binding defect as therapeutic agents and methods for treatment of abnormal physiological states
ES2228413T3 (es) * 1999-07-23 2005-04-16 Pfizer Products Inc. Productos intermedios y un procedimiento para producir agonistas de receptores beta-adrenergicos.
US20040265991A1 (en) * 2001-10-17 2004-12-30 Naoaki Taoka Process for preparation of (s)-alpha-halomethylpyridine-methanol derivatives
BR0307996A (pt) 2002-02-27 2004-12-07 Pfizer Prod Inc Processos e intermediários úteis na preparação de receptores de agonistas beta3-adrenérgicos
US6864268B2 (en) 2002-02-27 2005-03-08 Pfizer Inc. β3 adrenergic receptor agonists
AU2003209527A1 (en) * 2002-02-27 2003-09-09 Pfizer Products Inc. Crystal forms of (r)-2-(2-(4-oxazol-4-yl-phenoxy)-ethylamino)-1-pyridin-3-yl-ethanol
EP1424079A1 (en) * 2002-11-27 2004-06-02 Boehringer Ingelheim International GmbH Combination of a beta-3-receptor agonist and of a reuptake inhibitor of serotonin and/or norepinephrine
ATE406363T1 (de) 2003-05-09 2008-09-15 Hoffmann La Roche Methylindole und methylpyrrolopyridine als alpha- 1-adrenerge agonisten
GB2431927B (en) 2005-11-04 2010-03-17 Amira Pharmaceuticals Inc 5-Lipoxygenase-activating protein (FLAP) inhibitors
US7977359B2 (en) 2005-11-04 2011-07-12 Amira Pharmaceuticals, Inc. 5-lipdxygenase-activating protein (FLAP) inhibitors
US8399666B2 (en) 2005-11-04 2013-03-19 Panmira Pharmaceuticals, Llc 5-lipoxygenase-activating protein (FLAP) inhibitors
EP2285803A4 (en) 2008-05-23 2011-10-05 Amira Pharmaceuticals Inc Inhibitor of 5-Lipoxygenase Activating Protein

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4358455A (en) 1980-12-23 1982-11-09 Merck & Co., Inc. Aralkylamindethanol heterocyclic compounds
US5019578A (en) 1987-11-27 1991-05-28 Merck & Co., Inc. β-adrenergic agonists
ATE154935T1 (de) * 1993-06-14 1997-07-15 Pfizer Zweite amine als antidiabetische mittel und für die behandlung von fettleibigkeit
IL113410A (en) 1994-04-26 1999-11-30 Merck & Co Inc Substituted sulfonamides having an asymmetric center and pharmaceutical compositions containing them
CA2220538A1 (en) * 1995-05-10 1996-11-14 Pfizer Inc. .beta.-adrenergic agonists
JPH11504649A (ja) 1995-05-10 1999-04-27 ファイザー・インコーポレーテッド β−アドレナリン作働性アゴニスト

Also Published As

Publication number Publication date
BR9712951A (pt) 1999-12-07
CA2270386C (en) 2004-08-03
ZA9710186B (en) 1999-05-12
EA199900375A1 (ru) 1999-12-29
GT199700118A (es) 1999-05-05
PE10299A1 (es) 1999-02-10
BG103393A (en) 2000-07-31
AU4634697A (en) 1998-06-03
JP2000504347A (ja) 2000-04-11
MA24401A1 (fr) 1998-07-01
AP805A (en) 2000-01-28
ID18898A (id) 1998-05-20
JP3510635B2 (ja) 2004-03-29
IL129688A0 (en) 2000-02-29
DE69735433D1 (de) 2006-05-04
MY132507A (en) 2007-10-31
AP9701147A0 (en) 1998-01-31
IS5029A (is) 1999-04-16
AR010584A1 (es) 2000-06-28
TR199901063T2 (xx) 1999-08-23
CO4930261A1 (es) 2000-06-27
CA2270386A1 (en) 1998-05-22
ATE319687T1 (de) 2006-03-15
US6291489B1 (en) 2001-09-18
PA8441401A1 (es) 2000-05-24
KR20000053314A (ko) 2000-08-25
CN1237160A (zh) 1999-12-01
UY24774A1 (es) 1998-05-05
NO992296D0 (no) 1999-05-12
YU22099A (sh) 2001-09-28
TNSN97172A1 (fr) 2005-03-15
WO1998021184A1 (en) 1998-05-22
HRP970612A2 (en) 1998-08-31
OA11044A (en) 2002-02-20
EP0938476A1 (en) 1999-09-01
EP0938476B1 (en) 2006-03-08

Similar Documents

Publication Publication Date Title
NO992296L (no) FremgangsmÕte for disubstituerte pyridiner
ATE269312T1 (de) N-(amidinophenyl)-n'-(subst.)-3h-2,4- benzodiazepin-3-on derivative als faktor xa inhibitoren
Yasuhara et al. Selective monodesulfonylation of N, N-disulfonylarylamines with tetrabutylammonium fluoride
MX9701893A (es) Nuevos inhibidores de la prostaglandinsintasa.
DK0946546T3 (da) Pyridin-2-yl-methylaminderivater, fremgangsmåde til fremstilling heraf og anvendelse heraf som lægemidler
UA6306A1 (uk) Спосіб одержання метиловіх ефірів 2-гетаріл-3-метоксіакрілової кислоти
DK0715628T3 (da) Substituerede azaindolyliden-forbindelser og fremgangsmåde til fremstilling deraf
BR9509665A (pt) Composto composições e métodos
DK0773943T3 (da) Forbindelser, der er anvendelige som antiproliferative midler og garft-inhibitorer
DE69433984D1 (de) Arylpiperazinderivate von indol als liganden der rezeptoren 5 ht1-like, 5 ht1b und 5 ht1d
NO985335L (no) 2,4-Diaminopyrimidinderivater
NO952205L (no) Heterocykliske karbamater, fremgangsmåte for fremstilling derav og medikamenter
NO924988L (no) Tiazolidinforbindelser som inneholder kinongrupper, og fremgangsmaate til fremstilling derav
DK0601486T3 (da) Cis-epoxidderivater, der er egnede som irreversible HIV-proteaseinhibitorer, og fremgangsmåde og mellemprodukter til deres
DK362584A (da) 1-substituerede 4-hydroxymethylpyrrolidinoner, fremgangsmaade til fremstilling deraf, farmaceutiske praeparater og mellemprodukter
DE60227421D1 (de) Rmazeutische zusammensetzung und verwendung davon
DK0552758T3 (da) N-5-Beskyttede 2,5-diamino-4,6-dichlorpyrimidiner og fremgangsmåde til deres fremstilling
EA200401099A1 (ru) Производные гетероциклического амида
DE69316392D1 (de) Azanoradamantane
AR003964A1 (es) Nuevos azepanos y homologos de su anillo, compuestos de partida para su preparacion, procedimiento para la elaboracion de dichos azepanos y sushomologos de anillo y composiciones farmaceuticas que los contienen.
DK0475352T3 (da) 3-(1H-Indazol-3-yl)-4-pyridinaminer, fremgangsmåde og mellemprodukter til deres fremstilling og deres anvendelse som lægemidler
DK0483633T3 (da) 8-Azabicyclo 3,2,1 octylalkylthiazoliddinoner, fremgangsmåde til deres fremstilling og deres anvendelse som lægemidler.
NO306714B1 (no) Krystallinsk, polymorf form av (S,S,S)-N-(1-[2-karboksy-3-(N2-mesyllysylamino)propyl]-1-cyklopentylkarbonyl)-tyrosin
MY132595A (en) Process for preparing dioxoazabicyclohexanes
KR970011576B1 (ko) 헤테로 방향족 아미드기를 가지는 벤즈이미다졸 유도체

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application